<DOC>
	<DOCNO>NCT01275092</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness clinical technical performance CorPath® 200 System delivery manipulation coronary guidewires stent/balloon system use percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>Evaluation Safety Effectiveness CorPath 200 System Percutaneous Coronary Interventions ( PCI )</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>General 1 . Subject 18 99 year age . 2 . Subject acceptable candidate PCI . 3 . Subject must clinical evidence ischemic heart disease positive functional study . 4 . Female subject must nonchild bear potential , able bear child , negative pregnancy test within 7 day prior CorPath procedure . 5 . The subject legal representative inform nature study agree provision provide write informed consent . Angiographic 1 . Study lesion single de novo native coronary artery lesion . This lesion may consist multiple lesion ( 10mm less diseased segment ) must completely cover single stent least 2.0mm normal segment proximal distal edge lesion . 2 . Study reference vessel diameter 2.5mm 4.0mm visual estimate . 3 . Study lesion length less equal 24.0mm visual estimate . 4 . Study lesion diameter show stenosis least 50 % visual estimate . General 1 . Subject require plan PCI CABG ( Coronary Artery Bypass Graft ) within 30 day follow CorPath procedure . 2 . Evidence acute myocardial infarction within 72 hour prior intend CorPath procedure . 3 . Subject document left ventricular ejection fraction &lt; 30 % . 4 . Subject undergone PCI within 72 hour prior CorPath procedure . 5 . Subject undergone PCI within 30 day prior CorPath procedure experience major adverse coronary event ( MACE ) serious adverse event ( SAE ) define protocol . 6 . Subject know hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , prasugrel , stainless steel , cobalt chromium , sensitivity contrast medium , include Visipaque™ , adequately premedicated manage clinically appropriate substitute . 7 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC ( white blood cell ) count &lt; 3,000 cells/mm3 ( e.g . thrombocytopenia , thrombocythemia , neutropenia leukopenia ) . 8 . Subject serum creatinine level &gt; 2.0 mg/dL eGFR ( estimate Glomerular Filtration Rate ) &lt; 30 ml/min measure within 7 day prior procedure . 9 . Subject suffer stroke within 30 day prior plan CorPath procedure . 10 . Subject active peptic ulcer upper gastrointestinal bleeding within 6 month prior plan CorPath procedure . 11 . Subject history bleed diathesis coagulopathy refuse blood transfusion . 12 . Subject currently participate another investigational drug drug/device device trial complete entire follow period . 13 . Femoral access possible . Angiographic 1 . Target lesion fully cover single stent . 2 . Subject require treatment one vessel . 3 . Any previous stent placement within 5.0 mm ( proximal distal ) target lesion . 4 . The study lesion require plan treatment directional coronary atherectomy ( DCA ) , laser , rotational atherectomy device except balloon dilatation prior stent placement . 5 . The study vessel evidence intraluminal thrombus . 6 . The study vessel evidence moderate severe tortuosity ( &gt; 90° ) proximal target lesion . 7 . The study lesion follow characteristic : Total occlusion . Ostial location . Is within 2.0 mm side branch measure &gt; 2.0 mm diameter . Located &lt; 45° bend vessel . Moderately severely calcify . Moderate severe calcification vessel proximal target lesion . Located native vessel distal anastomosis , saphenous vein graft left/right internal mammary artery ( LIMA/RIMA ) bypass , approach bypass graft . 8 . Unprotected leave main coronary artery disease define obstruction great 50 % diameter stenosis leave main coronary artery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>robotic-assisted PCI</keyword>
	<keyword>coronary intervention</keyword>
	<keyword>CorPath PRECISE</keyword>
	<keyword>PCI</keyword>
</DOC>